| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2023 | 26.42% | UBS | $13 → $10 | Upgrades | Neutral → Buy |
| 11/06/2023 | 1.14% | Piper Sandler | $9 → $8 | Maintains | Neutral |
| 10/31/2023 | 89.63% | Canaccord Genuity | $17 → $15 | Maintains | Buy |
| 10/31/2023 | 39.06% | Cantor Fitzgerald | $14 → $11 | Upgrades | Neutral → Overweight |
| 10/24/2023 | 26.42% | Morgan Stanley | $13 → $10 | Maintains | Equal-Weight |
| 10/16/2023 | 13.78% | Piper Sandler | $13 → $9 | Maintains | Neutral |
| 09/29/2023 | 13.78% | Barclays | $14 → $9 | Maintains | Equal-Weight |
| 09/28/2023 | 39.06% | Bernstein | → $11 | Initiates Coverage On | → Outperform |
| 09/26/2023 | 76.99% | Cantor Fitzgerald | → $14 | Reiterates | Neutral → Neutral |
| 08/22/2023 | 76.99% | Cantor Fitzgerald | → $14 | Reiterates | Neutral → Neutral |
| 08/04/2023 | 64.35% | Morgan Stanley | $13 → $13 | Reiterates | Equal-Weight → Equal-Weight |
| 08/03/2023 | 64.35% | Morgan Stanley | $12 → $13 | Maintains | Equal-Weight |
| 06/30/2023 | 114.92% | Goldman Sachs | → $17 | Initiates Coverage On | → Buy |
| 06/05/2023 | 114.92% | Canaccord Genuity | $14 → $17 | Maintains | Buy |
| 05/10/2023 | 76.99% | Barclays | → $14 | Initiates Coverage On | → Equal-Weight |
| 05/04/2023 | 51.71% | Morgan Stanley | $10 → $12 | Maintains | Equal-Weight |
| 05/03/2023 | 114.92% | TD Cowen | $15 → $17 | Maintains | Outperform |
| 05/03/2023 | 64.35% | Cantor Fitzgerald | $12 → $13 | Maintains | Neutral |
| 03/31/2023 | 89.63% | TD Cowen | $13 → $15 | Upgrades | Market Perform → Outperform |
| 01/05/2023 | 51.71% | Scotiabank | → $12 | Initiates Coverage On | → Sector Outperform |
| 11/16/2022 | 76.99% | Canaccord Genuity | $12 → $14 | Maintains | Buy |
| 08/17/2022 | -5.18% | Piper Sandler | $6 → $7.5 | Maintains | Neutral |
| 05/16/2022 | -24.15% | Piper Sandler | $13 → $6 | Maintains | Neutral |
| 05/06/2022 | 76.99% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 02/16/2022 | 405.69% | Canaccord Genuity | $45 → $40 | Maintains | Buy |
| 09/27/2021 | 468.9% | Canaccord Genuity | → $45 | Initiates Coverage On | → Buy |
| 08/04/2021 | 418.33% | Morgan Stanley | $45 → $41 | Maintains | Equal-Weight |
| 02/12/2021 | 468.9% | Morgan Stanley | $12 → $45 | Maintains | Equal-Weight |
| 02/11/2021 | 557.4% | Piper Sandler | $20 → $52 | Upgrades | Neutral → Overweight |
| 11/04/2020 | 51.71% | Morgan Stanley | $7 → $12 | Maintains | Equal-Weight |
| 11/03/2020 | — | Piper Sandler | Downgrades | Overweight → Neutral | |
| 10/02/2020 | 89.63% | JP Morgan | → $15 | Upgrades | Neutral → Overweight |
| 10/01/2020 | 51.71% | Piper Sandler | $6 → $12 | Maintains | Overweight |
| 09/09/2020 | -11.5% | Morgan Stanley | → $7 | Initiates Coverage On | → Equal-Weight |
| 06/02/2020 | -36.79% | Cantor Fitzgerald | → $5 | Assumes | → Overweight |
| 03/09/2020 | -36.79% | Cantor Fitzgerald | → $5 | Assumes | → Overweight |
| 10/15/2019 | 1.14% | Piper Sandler | → $8 | Upgrades | Neutral → Overweight |
| 04/02/2019 | 1.14% | Stephens & Co. | → $8 | Downgrades | Overweight → Equal-Weight |
| 01/04/2019 | — | Cowen & Co. | Downgrades | Outperform → Market Perform |
What is the target price for Pacific Biosciences (PACB)?
The latest price target for Pacific Biosciences (NASDAQ: PACB) was reported by UBS on November 17, 2023. The analyst firm set a price target for $10.00 expecting PACB to rise to within 12 months (a possible 26.42% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pacific Biosciences (PACB)?
The latest analyst rating for Pacific Biosciences (NASDAQ: PACB) was provided by UBS, and Pacific Biosciences upgraded their buy rating.
When is the next analyst rating going to be posted or updated for Pacific Biosciences (PACB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacific Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacific Biosciences was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.
Is the Analyst Rating Pacific Biosciences (PACB) correct?
While ratings are subjective and will change, the latest Pacific Biosciences (PACB) rating was a upgraded with a price target of $13.00 to $10.00. The current price Pacific Biosciences (PACB) is trading at is $7.91, which is out of the analyst's predicted range.